因塞特 INCY 深 滬
已收盤 08-07 16:00:00 美东时间
120.56
+2.180
+1.84%
華盛通- 最 高120.88
- 今 開118.56
- 成交量 154.04万股
- 最 低 117.38
- 昨 收 118.38
- 總市值 244.37亿
- 52周最高 132.60
- 市盈率 靜 18.81
- 換手率 0.76%
- 52周最低 81.09
- 委 比 -12.72%
- 總股本 2.03亿
- 歷史最高 153.15
- 量 比 0.81
- 振 幅 2.96%
- 歷史最低 11.76
- 每 手 1
- 風險率 10.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays raised the price target for Darling Ingredients Inc (NYSE:DAR) from $62 to $65. Barclays analyst Ther...
08-03 20:16
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
08-03 18:18
Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte Corp. (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance. The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 b...
07-29 22:53
财报速睇 | 因塞特 2026财年Q2营收16.74亿美元，同比增长37.7%；归母净利润5.86亿美元，同比增长44.6%
华盛资讯7月29日讯，因塞特公布2026财年Q2业绩，公司Q2营收16.74亿美元，同比增长37.7%，归母净利润5.86亿美元，同比增长44.6%。
07-29 06:32
药企因塞特展现强劲商业化势头 营收猛增38%并上调全年预期
生物制药公司因塞特（Incyte Corp （INCY））周二公布的第二季度财报显示，得益于核心产品的全面增长以及与政府就Opzelura返款纠纷达成和解带...
07-29 03:15
Incyte Says It's No Longer A One-Drug Story
Incyte Corp. (NASDAQ:INCY) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opzelura and its hematology and oncology products. The biopharmaceutical company repor...
07-29 03:10
Incyte raises sales outlook as Opzelura, cancer portfolio fuel strong quarter
Incyte (INCY) raised its full-year sales guidance on Tuesday after reporting second-quarter revenue and earnings that topped Wall Street expectations, driven by strong demand across its commercial por...
07-28 21:29
ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC’s “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, picked ServiceNow, Inc. (NYSE:NOW). Lending support to his choice, ServiceNow, on July 23, reported strong second-quarter earnings. Adjusted EPS of 90 cents beat the Street estima...
07-28 20:18
财报速睇 | 因塞特2026财年Q2营收16.74亿美元，同比增长37.7%；归母净利润5.86亿美元，同比增长44.6%
华盛资讯7月28日讯，因塞特公布2026财年Q2业绩，公司Q2营收16.74亿美元，同比增长37.7%，归母净利润5.86亿美元，同比增长44.6%。
07-28 19:51
